The primary role of the Biostatistics and Data Management Core is to provide collaboration on quantitative aspects of the design, conduct, and analysis of the clinical and laboratory studies undertaken as part of this proposal. In both the laboratory and the clinical studies this will include sample size calculation and analysis of data for abstracts manuscripts and presentations. For the clinical studies, will also include sample size calculation and analysis of data for abstracts, manuscripts and presentations. For the clinical studies, will till also include protocol review, forms development, dat extraction, data computerization and quality control.
Specific aims of the core include: 1. To provide biostatistical expertise for clinical protocol design and for planning and interpreting sequences of related protocols. 2. To provide biostatistical assistance in the design, analysis, and interpretation of laboratory studies. 3. To provide forms design, data management support, and quality control for clinical protocols. 4. To provide clinical data management for collection of individual patient information. 5. To provide interim reports for ongoing studies, and more detailed statistical analyses of finally study results; to collaborate on dissemination of these results through abstracts, manuscripts, and presentations. 6. To conduct statistical analyses using the BMT data base to compare outcomes and identify prognostic factors across protocols when appropriate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI029530-12
Application #
6611103
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-08-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
$247,465
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Exley, Mark A; Friedlander, Phillip; Alatrakchi, Nadia et al. (2017) Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res 23:3510-3519
Matsuoka, Ken-ichi; Koreth, John; Kim, Haesook T et al. (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5:179ra43
Brown, J R; Kim, H T; Armand, P et al. (2013) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27:362-9
Jacobson, Caron A; Turki, Amin T; McDonough, Sean M et al. (2012) Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 18:565-74
Kawano, Yutaka; Kim, Haesook T; Matsuoka, Ken-Ichi et al. (2011) Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood 118:5021-30
Koreth, John; Matsuoka, Ken-ichi; Kim, Haesook T et al. (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055-66
Schoenfeld, Jonathan D; Dranoff, Glenn (2011) Anti-angiogenesis immunotherapy. Hum Vaccin 7:976-81
Brown, Julia A; Stevenson, Kristen; Kim, Haesook T et al. (2010) Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 115:4111-9
Matsuoka, Ken-ichi; Kim, Haesook T; McDonough, Sean et al. (2010) Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 120:1479-93
Sarantopoulos, Stefanie; Stevenson, Kristen E; Kim, Haesook T et al. (2009) Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113:3865-74

Showing the most recent 10 out of 15 publications